We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.68B
1-Year Est. Return 375.52%
This Fund
S&P 500
This Quarter Est. Return
+17.76%
1 Year Est. Return
+375.52%
3 Year Est. Return
+2,120.72%
5 Year Est. Return
+8,694.03%
10 Year Est. Return
–
AUM
$379M
AUM Growth
+$92.3M
Cap. Flow
+$98.3M
Cap. Flow %
25.91%
Top 10 Hldgs %
63.93%
Holding
34
New
5
Increased
14
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$35.7M
2
MRUS
Merus
MRUS
+$15.4M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$12.3M
4
TNYA icon
Tenaya Therapeutics
TNYA
+$11M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$10.9M

Top Sells

Rank Stock Value
1
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$14.9M
2
MGNX icon
MacroGenics
MGNX
+$10.6M
3
EPIX
ESSA Pharma
EPIX
+$8.05M
4
MRSN
Mersana Therapeutics
MRSN
+$5.83M
5
CLDX icon
Celldex Therapeutics
CLDX
+$3.53M

Sector Composition

Rank Sector Weight
1 Healthcare 99.34%
2 Financials 0.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IVA
26
Inventiva
IVA
$1.05B
$3.72M 0.98%
262,658
– –
BLSA
27
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$2.49M 0.66%
250,000
– –
ATXS
28
DELISTED
Astria Therapeutics
ATXS
$2.12M 0.56%
239,270
-30,230
-11% -$290K
SPRY icon
29
ARS Pharmaceuticals
SPRY
$520M
$969K 0.26%
97,143
– –
EPIX
30
DELISTED
ESSA Pharma
EPIX
– –
-281,911
Closed -$8.05M
MCRB icon
31
Seres Therapeutics
MCRB
$53M
– –
-7,273
Closed -$3.47M
MGNX icon
32
MacroGenics
MGNX
$262M
– –
-393,850
Closed -$10.6M
MRSN
33
DELISTED
Mersana Therapeutics
MRSN
– –
-17,169
Closed -$5.83M
CNST
34
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
– –
-440,869
Closed -$14.9M
1
2

Similar funds

TNBTD
Trustmark National Bank Trust Department Jackson, Mississippi $1.68B AUM 19.26% 1-Year Est. Return
PWMAG
Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.68B AUM 31.18% 1-Year Est. Return
SH
Spear Holdings Dubai, United Arab Emirates $1.68B AUM 4.3% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
HCA
Heck Capital Advisors Rhinelander, Wisconsin $1.67B AUM 26.33% 1-Year Est. Return

Commodore Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Commodore Capital held 34 positions worth $379M, up 32% from $287M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Commodore Capital deployed $98.3M of net new capital in Q3 2021, opening 5 new positions and adding to 14 existing holdings. Its largest new stake was Dicerna Pharmaceuticals, Inc.: 1,292,251 shares worth $26.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Celldex Therapeutics, an estimated $3.53M trimmed.

  • Commodore Capital's largest Q3 2021 buy was Dicerna Pharmaceuticals, Inc.: 1,292,251 shares worth $26.1M.
  • Commodore Capital added most to Protagonist Therapeutics in Q3 2021, an estimated $12.3M increase.
  • Commodore Capital's biggest Q3 2021 reduction was Celldex Therapeutics, cutting an estimated $3.53M.
  • Commodore Capital fully exited Constellation Pharmaceuticals, Inc. in Q3 2021, selling an estimated $14.9M.
  • Commodore Capital's ten largest holdings make up 64% of its $379M portfolio in Q3 2021.
  • Commodore Capital opened 5 new positions and closed 5 in Q3 2021.
  • Commodore Capital's portfolio value rose 32% quarter-over-quarter to $379M.

Based on Commodore Capital's 13F filing for Q3 2021, filed 15 Nov 2021.